본문 바로가기

Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
EClinicalMedicine73 · 2024
피인용
Web of Science 11Scopus 13
FWCI (Scopus)
2.02
JCR IF
JCR 2023 9.6
ISSN
2589-5370

저자

  1. Sohn, Won제1저자Sungkyunkwan Univ, Kangbuk Samsung Hosp, Seoul, South Korea
  2. Park, Soo YoungKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea
  3. Lee, Tae HeeKonyang Univ, Coll Med, Daejeon, South Korea
  4. Chon, Young EunCHA Univ, CHA Bundang Med Ctr, Seongnam, South Korea
  5. Kim, In HeeChonbuk Natl Univ, Chonbuk Natl Univ Hosp, Med Sch, Jeonju, South Korea
  6. Lee, Byung-SeokChungnam Natl Univ, Chungnam Natl Univ Hosp, Sch Med, Daejeon, South Korea
  7. 윤기태Pusan Natl Univ, Yangsan Hosp, Coll Med, Yangsan, South Korea
  8. Jang, Jae YoungSoonchunhyang Univ, Inst Digest Res, Coll Med, Digest Dis Ctr, Seoul, South Korea
  9. Lee, Yu RimKyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea
  10. Yu, Su JongSeoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea
  11. Choi, Won-MookUniv Ulsan, Coll Med, Liver Ctr, Asan Med Ctr, Seoul, South Korea
  12. Kim, Sang GyuneSoonchunhyang Univ, Hosp Bucheon, Coll Med, Bucheon, South Korea
  13. Jun, Dae WonHanyang Univ, Hanyang Univ Hosp, Coll Med, Seoul, South Korea
  14. Jeong, JoonhoUlsan Univ, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea
  15. Kim, Ji HoonKorea Univ, Guro Hosp, Coll Med, Seoul, South Korea
  16. Jang, Eun SunSeoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
  17. Kim, Hwi YoungEwha Womans Univ, Coll Med, Seoul, South Korea
  18. Cho, Sung BumChonnam Natl Univ, Chonnam Natl Univ Hosp, Hwasun, South Korea
  19. Jang, Byoung KukKeimyung Univ, Sch Med, Daegu, South Korea
  20. Park, Jung GilYeungnam Univ, Coll Med, Daegu, South Korea
  21. Lee, Jin-WooInha Univ, Inha Univ Hosp, Sch Med, Incheon, South Korea
  22. Seo, Yeon SeokKorea Univ, Anam Hosp, Coll Med, Seoul, South Korea
  23. Il Lee, JungYonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea
  24. Song, Do SeonCatholic Univ Korea, St Vincents Hosp, Coll Med, Suwon, South Korea
  25. Kim, Moon YoungYonsei Univ, Wonju Coll Med, Wonju, South Korea
  26. Yim, Hyung JoonKorea Univ, Ansan Hosp, Coll Med, Ansan, South Korea
  27. Sinn, Dong HyunSungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
  28. Ahn, Sang HoonYonsei Univ, Wonju Coll Med, Wonju, South Korea
  29. Kim, Young SeokSoonchunhyang Univ, Hosp Bucheon, Coll Med, Bucheon, South Korea
  30. Jang, HeejoonSeoul Natl Univ, Coll Med, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea
저자 33명 모두 보기

초록

Background: It is unclear whether direct-acting antivirals (DAAs) treatment improves the disease burden in hepatitis C virus (HCV) infection. This study aimed to investigate the effect of DAA treatment on the reduction of disease burden in patients with HCV infection using individual participant data. Methods: This nationwide multicentre retrospective cohort study recruited patients with HCV infection from 29 tertiary institutions in South Korea. The data collection was done from medical records in each institution. The study included the untreated patients and the DAAs-treated patients and excluded those with a history of interferon-based treatments. Disease burden was the primary outcome, as represented by disability-adjusted life years (DALYs). Improvement in fibrosis after DAA treatment was assessed using APRI, FIB-4 index, and liver stiffness (LS) as assessed by transient elastography. Clinical outcomes were hepatocellular carcinoma (HCC), decompensation, and mortality. Findings: Between January 1, 2007, and February 17, 2022, data from 11,725 patients with HCV infection, 8464 (72%) of whom were treated with DAAs, were analysed. DAA treatment significantly improved APRI- (median 0.64 [interquartile range (IQR), 0.35–1.31]–0.33 [0.23–0.52], p < 0.0001), FIB-4- (median 2.42 [IQR, 1.48–4.40]–1.93 [1.31–2.97], p < 0.0001), and liver LS-based fibrosis (median 7.4 [IQR, 5.3–12.3]–6.2 [4.6–10.2] kPa, p < 0.0001). During the median follow-up period of 27.5 months (IQR, 10.6–52.4), 469 patients died (4.0%), 586 (5.0%) developed HCC, and 580 (4.9%) developed decompensation. The APRI-based DALY estimate was significantly lower in the DAA group than in the untreated group (median 4.55 vs. 5.14 years, p < 0.0001), as was the FIB-4-based DALY estimate (median 5.43 [IQR, 3.00–6.44] vs. 5.79 [3.85–8.07] years, p < 0.0001). The differences between the untreated and DAA groups were greatest in patients aged 40–60 years. In multivariable analyses, the DAA group had a significantly reduced risk of HCC, decompensation, and mortality compared with the untreated group (hazard ratios: 0.41 [95% confidence interval (CI), 0.34–0.48], 0.31 [95% CI, 0.30–0.38], and 0.22 [95% CI, 0.17–0.27], respectively; p < 0.0001). Interpretation: Our findings suggest that DAA treatment is associated with the improvement of liver-related outcomes and a reduction of liver fibrosis-based disease burden in patients with HCV infection. However, further studies using liver biopsy are needed to clarify the effect of DAA treatment on the reduction in the exact fibrosis-based disease burden beyond noninvasive tests. Funding: The Korea Disease Control and Prevention Agency.

키워드

Direct-acting antiviralDisease burdenHepatitis C virusLiver fibrosisSIMPLE NONINVASIVE INDEXSIGNIFICANT FIBROSISLIVER FIBROSISELASTOGRAPHYPREDICT

식별자

Scopus EID
2-s2.0-85194404227
WoS UID
001250292400001